Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 13/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.42 |
| ▸ | CALCR | P30988 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629285 | 0.91 | KEAP1 (0.50) | KEAP1ACERENNAA50 | |
| SCHEMBL30629284 | 0.90 | KEAP1 (0.51) | KEAP1ACERENNAA50 | |
| SCHEMBL30763704 | 0.89 | KEAP1 (0.56) | KEAP1ACERENRAMP3CALCR | |
| SCHEMBL30800558 | 0.88 | ACE (0.54) | KEAP1ACEREN | |
| SCHEMBL30434874 | 0.81 | ACE (0.54) | ACEREN | |
| SCHEMBL30434139 | 0.81 | ACE (0.54) | ACEREN | |
| SCHEMBL29520988 | 0.81 | ACE (0.47) | KEAP1ACERENRAMP3CALCR | |
| SCHEMBL14567377 | 0.81 | ACE (0.58) | ACEREN | |
| SCHEMBL5491754 | 0.81 | ACE (0.58) | ACEREN | |
| SCHEMBL30678853 | 0.80 | REN (0.44) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126242-A | Heptapeptides, compositions and uses thereof | 深圳市维琪科技股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-117126242-B | Heptapeptides, compositions and uses thereof | 深圳市维琪科技股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117126242-A | Heptapeptides, compositions and uses thereof | 深圳市维琪科技股份有限公司 | 2023-11-28 | — | — | CN | disclosed |